Law360, New York (April 12, 2005, 12:00 AM ET) -- Shire Pharmaceuticals Group has decided not to sue Israeli generics maker Teva Pharmaceuticals USA Inc. over its application for a generic version of the best-selling attention deficit drug Adderall XR.
In February, Shire said that it had received a Paragraph IV Notice letter from Teva advising of the filing of an Abbreviated New Drug Application for its amphetamine combination product, a generic version of Shire's Adderall XR, a mixed amphetamine salts product.
Shire has filed lawsuits against generics makers Barr Laboratories and Impax, the first two...
Shire Opts Not To Sue Teva Over Adderall XR ANDA
To view the full article, take a free trial now.
